Key Highlights

  • STTK closed at $4.87 on June 2, 2026, down 13.81%, after shareholders approved an Equity plan boost that raises near-term dilution risk for existing holders.
  • The company's lead programme SL-325, a potentially first-in-class DR3 blocking antibody for inflammatory bowel disease, has completed Phase 1 enrollment with Q2 clinical data due.
  • STTK carries EPS of -$0.56 and a 52-week range of $0.71 to $8.33, reflecting the binary risk profile of a clinical-stage immunotherapy company at an inflection point in its development timeline.

Dilution Concern Meets Sector Pressure

Shares of Shattuck Labs, Inc. (Nasdaq: STTK) closed at $4.87 on June 2, 2026, a loss of $0.78 or 13.81% on Volume of 831,200 shares. Founded in 2016 and headquartered in Austin, Texas, Shattuck Labs is a clinical-stage biotechnology company developing novel biologic therapies for inflammatory and immune-mediated diseases, with a lead programme targeting the clinically validated TL1A/DR3 pathway and a secondary oncology focus through its TRIM7 inhibitor programme. Two concurrent pressures drove the session: a same-day Shareholder vote approving an equity plan expansion, and broader biotech sector weakness.

The Equity Plan Approval

On June 2, 2026, Shattuck Labs shareholders approved a boost to the company's equity incentive plan alongside the annual say-on-pay vote. Equity plan expansions authorise additional shares for issuance, typically to fund employee compensation and future Capital raises. For a clinical-stage company with no commercial Revenue, approval of additional share authorisation signals that dilutive issuances may be forthcoming, a prospect that historically weighs on near-term price action as existing shareholders reassess their percentage ownership.

Clinical Programme Context

Shattuck's lead asset, SL-325, is a potentially first-in-class monoclonal antibody blocking death receptor 3, a clinically validated target in the TL1A/DR3 pathway with strong genetic association to inflammatory bowel disease. The programme is currently in Phase 1 Clinical Trials and has completed enrollment in its Crohn's disease cohort, with Q2 2026 data expected. An FDA Orphan Drug designation, confirmed in late May 2026, further validates the programme's differentiated mechanism and provides regulatory and commercial incentives if development succeeds.

The company is also advancing SL-425, a half-life extended version of SL-325, multiple preclinical DR3-based bispecific antibodies targeting IBD and other immune-mediated indications, and a TRIM7 inhibitor in oncology, providing pipeline breadth beyond the lead asset.

Valuation and Risk Profile

STTK carries a Market Capitalisation of approximately $233 million, EPS of -$0.56, and a 52-week range of $0.71 to $8.33. The stock opened at $5.60 and sold off through the session, a pattern consistent with equity plan dilution concerns rather than clinical deterioration. The company operates R&D facilities in Durham, North Carolina alongside its Austin headquarters and employs 44 full-time staff, a lean operational structure for a multi-programme clinical-stage biotech.

The pending Q2 data readout for the SL-325 Crohn's cohort represents the most significant near-term binary event for the stock. Positive efficacy signals in the TL1A/DR3 pathway would validate Shattuck's differentiated approach in a competitive IBD landscape that includes larger-capitalised programmes from AstraZeneca, Roche, and Prometheus Biosciences.

Conclusion

The 13.81% decline in STTK reflects a combination of near-term dilution concern from the equity plan approval and the broader biotech sector pressure that characterised June 2 trading. The clinical fundamentals remain intact. Enrollment completion, an orphan drug designation, and an imminent Q2 data readout collectively represent a meaningful near-term catalyst package. The equity plan expansion is a manageable structural negative, but the market's reaction illustrates how sensitively pre-revenue biotechs respond to any signal of future share count growth ahead of a key data readout.